Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Would if it was going to happen the TO company would wait until news of agile and if going into that then make the offer ? Also would be interesting to see if they would take 737 forward as like it’s been said many times gathering dust with Sierra .A few exciting weeks ahead
GLA
Come on the SAR
Gunner as far as I can see it if a company were interested in a takeover, the doubt of concrete success would make a buyout offer considerably less until the results of Agile are known. Should the results prove between positive and exceptional then that would be the point that an offer would be made. Companies just do not like uncertainty as can prove very costly. A company stumping up several billion plus would need to know that what they are getting, will generate a decent revenue to cover their costs and increase the market cap of their company.
For all we know informal offers may well be on going. These we will never get to know about. If and when a formal offer is made that would be released via an RNS. This however does not stop another company offering a more attractive deal. A bidding war so as to speak.
Should these type of discussions be taking place then very likely information of this nature will leak out. Not by Sar I might add.
The Chat board here has become a pleasure to visit again. I note a lack of input today by the latest LSE newbies who post nothing but disruptive cartloads of misinformed rubbish. It does appear that they do want to drive the SP down to purchase at the lowest price available, either for themselves or someone else.
Regards
Cheers SOG my view was if they brought when ,if it got agile backing after seeing what other same style drugs do at the minute but not jak1 and a free ride through p1 2 and 3 which would normally cost millions and if the science is as good as we hope then getting in early before the results are released and the amount of time invested saved due to the 10 years plus already done it could be a good gamble and would they be able recoup the loss if failed through tax ?
Just my view
GLA
Come on the SAR
You are welcome gunner. Most important aspect in our Tyk2 Jak 1 is we are nigh entirely Tyrosine Kinase Inhibitor with a small amount ( I am sure Tim referred to as an optimal amount) of Jak1.
Jak 2 and Jak3 have known serious side affects. The US has previously issued black box warnings indicating this. They have granted some 1st generation inhibitors Emergency Use Administration (EUA), ie to prevent death, but many are loosing this due to very limited effectiveness and severe side affects down the line. AS much as I can see from my very limited knowledge of bio chemistry all looks very, very promising.
I have posted below some c...womble fodder below.
No mention of SDC1801
No mention of SRA737 clinical trials
All very negative and doubt inducing
https://uk.finance.yahoo.com/news/going-sareum-holdings-share-price-132317020.html
Regards
Cheers SOG appreciated have a good weekend and let’s look forward to the following week and maybe even a red dot moment
GLA
I have copied this excerpt below from the patent of Sareums Tyk2 inhibitor. Originally found and posted by Krohn.
ref:-
https://worldwide.espacenet.com/patent/search/family/047754367/publication/EP2634185A1?q=pn%3DEP2634185
'Contrary to reports in TYK2-/- mice, signalling by a wide variety of cytokines was found to be impaired thus highlighting non-redundant roles for human TYK2 in the function of Type I IFNs, IL-6, IL-10, IL-12 and IL- 23. An imbalance in T helper cell differentiation was also observed, with the patient's T cells exhibiting an extreme skew towards the development of IL-4 producing Th2 cells and impaired Thl differentiation. Indeed, these cytokine signalling defects could be responsible for many of the clinical manifestations described, for example atopic dermatitis and elevated IgE levels (enhanced Th2), increased incidence of viral infections (IFN defect), infection with intracellular bacteria (IL-12/Thl defect) and extracellular bacteria (IL-6 and IL-23/Thl7 defect). Emerging evidence from genome-wide association studies suggests that single nucleotide polymorphisms (SNPs) in the TYK2 gene significantly influence autoimmune disease susceptibility.'
Regards